Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22009
Title: Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study.
Authors: Buckley, Rachel F;Sikkes, Sietske;Villemagne, Victor L;Mormino, Elizabeth C;Rabin, Jennifer S;Burnham, Samantha;Papp, Kathryn V;Doré, Vincent;Masters, Colin L;Properzi, Michael J;Schultz, Aaron P;Johnson, Keith A;Rentz, Dorene M;Sperling, Reisa A;Amariglio, Rebecca E
Affiliation: Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA
Department of Neurology, Stanford University, Palo Alto, CA, USA
Department of Epidemiology and Biostatistics, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, the Netherlands
The Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
The Australian eHealth Research Centre, CSIRO Health & Biosecurity, Brisbane, Queensland, Australia
The Australian eHealth Research Centre, CSIRO Health & Biosecurity, Melbourne, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Melbourne School of Psychological Science, University of Melbourne, Melbourne, Victoria, Australia
Alzheimer Center and Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, the Netherlands
Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Issue Date: Dec-2019
EDate: 2019-12
Citation: Alzheimer's & Dementia (Amsterdam, Netherlands) 2019; 11: 670-678
Abstract: We aimed to examine the contribution of subjective cognitive decline (SCD) to reduce the number of β-amyloid (Aβ) positron emission tomography scans required for recruiting Aβ+ clinically normal individuals in clinical trials. Three independent cohorts (890 clinically normal: 72 yrs ± 6.7; Female: 43.4%; SCD+: 24%; apolipoprotein E [APOE] ε4+: 28.5%; Aβ+: 32%) were used. SCD was dichotomized from one question. Using logistic regression, we classified Aβ+ using the SCD dichotomy, APOEε4, sex, and age. SCD increased odds of Aβ+ by 1.58 relative to non-SCD. Female APOEε4 carriers with SCD exhibited higher odds of Aβ+ (OR = 3.34), whereas male carriers with SCD showed a weaker, opposing effect (OR = 0.37). SCD endorsement reduces the number of Aβ positron emission tomography scans to recruit Aβ+ individuals by 13% and by 9% if APOEε4 status is known. SCD helps to classify those with high Aβ, even beyond the substantial effect of APOE genotype. Collecting SCD is a feasible method for targeting recruitment for those likely on the AD trajectory.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22009
DOI: 10.1016/j.dadm.2019.08.004
PubMed URL: 31673597
ISSN: 2352-8729
Type: Journal Article
Subjects: APOEε4
Alzheimer's disease
Amyloid
Subjective cognitive decline
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.